3-aminomethyl-5-methyl-hexanoic acid binds with high affinity and specificity to the alpha(2)-delta subunit protein of voltage-gated calcium channels in CNS tissues and acts as a presynaptic modulator of excitatory neurotransmitter release by inhibiting calcium influx. 5 Although it is a structural analogue of GABA, it does not act on GABA receptors or GABA uptake. 6 Four multi-centre, prospective randomized double-blind placebo-controlled trials confirmed anticonvulsant efficacy against partial-onset seizures in a total of 1396 patients. 7 The responder rate (i.e., percentage of patients with 50% or more reduction in seizure frequency vs. baseline) in these studies ranged from 14% to 51% of the enrolled patients. In addition to somnolence, dizziness, and ataxia, an increase in bodyweight of 7% or more of the baseline body weight was reported as an adverse effect in about 14% of the patients at a dose of 600 mg/day. 4 In Germany, pregabalin was available for add-on treatment of epilepsy in adult patients since September 2004. We wanted to assess the therapeutic and side effects right from the start of marketing. Furthermore, being aware of the bodyweight gain issue and its negative implications, we embedded a randomized controlled trial to test the hypothesis that more extended counseling of the patients may help to prevent this adverse effect. This counseling addressed the need for a weekly bodyweight control as well as appropriate behavioral counter-measures in case of bodyweight gain such as diet control (less energy up-take) and physical exercise (more energy expenditure).
Methods

Randomized controlled trial
We defined two groups of patients. In one group patients received extended counseling on the risk of bodyweight gain during pregabalin add-on therapy before titration. Extended counseling comprised a comprehensive description of this risk factor and a discussion of possible behavioral interventions that may allow the patient to prevent weight gain. In particular, the patients were asked to check their bodyweight once a week and to react in case of substantial bodyweight gain by reducing ingestion and by increasing energy consumption (e.g., physical exercise). Patients received a written handout with the essentials of these explanations (see Appendix A). The study design did not allow controlling patient compliance. In the other experimental group patients were generally informed about all possible risks of pregabalin treatment including bodyweight gain according to the clinical standards. However, no particular emphasis was placed on bodyweight gain and no suggestions to check bodyweight or to react in case of bodyweight gain were given by the physician. The patients in the second group did not receive the handout. Patients were randomly allocated to either group. The follow-up examinations were scheduled for 3 and 6 months.
Baseline medication and pregabalin titration
It was intended that baseline medication generally remains unchanged during the study if possible, but clinically reasonable adaptations were permitted within the protocol. Pregabalin was slowly titrated with a daily dosage increment of 75 mg/week (0-0-1, 1-0-1, 1-0-2, 2-0-2 and so on) thus reaching the prescribed dosage of 300 or 450 mg/day after 4 or 6 weeks, respectively. Depending on seizure outcome and adverse side effects at the 3-month follow-up the dosage was further up or down-titrated according to the same regimen.
Patients
From September 2004 to May 2005, adult outpatients who appeared to be appropriate candidates for pregabalin add-on treatment were asked to participate in the study. From 140 adult patients receiving pregabalin during this period, 98 patients (70%) gave written informed consent and were enrolled in the study. The general and clinical data of these patients are given in Table 1 .
Methods and measures
Bodyweight and body height were determined at baseline in all patients. The body mass index (BMI) was calculated (BMI (kg/cm All patients were asked to fill-out the Adverse Event Profile questionnaire. 8 This questionnaire comprises 19 frequent adverse events including bodyweight gain (item #14). Seizure frequency per month was calculated from the patients' seizure diaries based on the last 3 months at baseline (retrospectively), 3-and 6-month follow-up. Simple partial seizures (SPS), complex partial seizures (CPS), generalized tonic-clonic seizures (GTCS) and drop attacks were counted separately.
Statistics
Baseline group differences were tested by non-parametric tests (x 2 -test, Mann-Whitney U-test). The hypothesis of this study was tested by univariate repeated measures ANOVA including bodyweight as dependent variable, the experimental condition (extended vs. standard counseling) as a group factor and time of measurement (baseline, 3-and 6-month follow-up) as the within-subject factor. Further tests were applied in an explorative way; non-parametric tests were preferred (Friedman test, Spearman's rank correlation and others). The significance level was defined by a = .05 for all statistical tests.
Results
Sixty-one patients (62%) completed the study protocol. Four and six patients dropped out for unknown reasons before the 3-and 6-month follow-up, respectively. In addition, 16 (16%) and 11 patients (11%) discontinued pregabalin medication before the 3-and 6-month follow-up, respectively (overall premature study exit rate: 38%). Four patients decided to withdraw from pregabalin at the study exit. The main reasons for premature study exits were side effects (18 patients, including weight gain: 2 patients) or lack of therapeutic effect (5 patients). The follow-up visits scheduled for 3 and 6 months were actually done at 3.4 (AE0.9; median 3.3) and 7.5 (AE1.7; median 7.0) months after baseline.
Medication
The average daily dosage of pregabalin was 296 (S.D. AE 92; median: 300) mg at the 3-month follow-up and 382 (S.D. AE 158) (median: 375) mg at the 6-month follow-up in patients who completed the study. The baseline medication was reduced in 14 and increased in 4 patients during the study but remained unchanged in the majority of patients (71%). Medication changes were not different for both experimental groups and only in one patient topiramate as a drug known to be associated with weight changes was reduced.
Bodyweight gain
Mean bodyweight (kg) and body mass indices during the study are shown in Table 2 . To avoid sample selection effects only patients who completed the study design were included. The bodyweight data were missing in one patient for the 6-month follow-up.
As compared to the baseline, the mean bodyweight increase in individual patients was 2.5 kg (S.D. AE 3.7 kg; median: 2.0 kg) and 4.0 kg (S.D. AE 4.1 kg; median: 4.0 kg; N = 60) at the 3-and 6-month follow-up, respectively. The body mass index increment was 0.9 (S.D. AE 1.3; median: 0.6) and 1.4 (S.D. AE 1.4; median: 1.3) for the 3-and 6-month follow-up, respectively. According to ICD-10 weight classes (low weight, normal weight, overweight, obesity grade I; see section Methods), 2 patients decreased their weight class but 11 and 13 patients changed to next higher weight class at the 3-and 6-month follow-up; at the 6-month follow-up 2 patients were even two classes higher as compared to their baseline category. Furthermore, 17 (28%) and 25 patients (41%) had a bodyweight gain of greater than 5 kg at the 3-and 6-month followup, respectively.
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Effects of counseling
For patients who completed the study, the randomization procedure yielded 26 patients with extended counseling and 35 patients with standard clinical counseling. No significant group differences regarding the general and clinical variables were obtained between both groups at the baseline (x 2 and Mann-Whitney tests). Baseline medication was changed in 11 patients from the extended counseling group and in 7 patients from the standard counseling group (x 2 -test, p = .15). A significant interaction effect of 'time Â experimental condition' (F = 5.2, p = .03) on pregabalin dosage (mg) indicated that the dosage was significantly more increased from the 3-to 6-month follow-up in the standard counseling group (291 AE 74 mg vs. 415 AE 164 mg) as compared to the extended counseling group (303 AE 113 mg vs. 338 AE 141 mg) which confounds the experimental factor 'counseling'. The mean bodyweight measures during the study of both groups are shown in Fig. 1 .
A repeated measures ANOVA revealed a significant main effect of the factor 'time' on bodyweight (kg) (F = 28.2, p < .001) indicating weight gain in the entire sample during the study. There was no main effect of the factor 'group' (F = 1.35, p = .25) and no interaction effect 'time Â group' (F = .16, p = .85) thus giving no evidence for an effect of the experimental counseling condition on bodyweight gain during the study.
Other factors
Pregabalin specific effects on bodyweight gain were tested but no correlations of weight gain (kg) with absolute dosage (mg), relative dosage (mg/kg, dosage divided by baseline bodyweight), or categorized dosage (more or less than 300 mg) of pregabalin were found at any time point throughout the study. Furthermore, neither baseline body measures nor the clinical variables were correlated with weight gain during the study. However, in an explorative analysis the number of baseline anticonvulsant medications turned out to be significantly correlated with weight gain from baseline to the 3-month follow-up (Spearman's rank correlation, r = .32, p < .05) indicating a role of the total drug load for bodyweight gain under pregabalin therapy (see Fig. 2 ).
Controlling the effects of the number of anticonvulsant drugs as a covariate in the repeated measures ANOVA yielded a different pattern of results. The main effect of 'time' was lost (F = 1.9, p = .16) but the interaction effect 'time -Â number of anticonvulsant drugs' was significant (F = 3.2, p < .05) indicating that weight gain might not depend on pregabalin per se but on interaction of pregabalin with a high anticonvulsant drug load. Again the experimental factor 'counseling condition' revealed no main effect, and did not interact with bodyweight gain. No specific pharmaceutical combination could be revealed as a risk factor for bodyweight gain.
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Seizure outcome and tolerability
The seizure outcome is given in Table 3 .
Responder rates are given related to both the according-to-protocol (N = 61) and the intent-totreat sample (N = 98). The median seizure %-reduction in study completers was 38% and 33% (N = 61) at the 3-and 6-month follow-up, respectively, indicating an early onset of the anticonvulsant effect. None of the patients who previously underwent epilepsy surgery (N = 10, 16%) experienced seizure response at the 6-month follow-up (x 2 = 8.9, p < .05). No other correlations with general or clinical variables were obtained. In particular, seizure outcome and bodyweight changes were not correlated.
As mentioned above, side effects were a major reason for the premature study exit. However, the Adverse Event Profile scores were unchanged by pregabalin (mean score of 40 for all time points, rate of patients with scores greater than 45 at about 30%). Bodyweight gain was neither correlated with Adverse Event Profile total score nor with item 14 (bodyweight gain).
Discussion
This study addressed bodyweight gain as a side effect of the new anticonvulsant pregabalin. Findings indicate a dosage independent and sustained effect of this drug on bodyweight during 6 months of observation with a group median of 4.0 kg. Fortyone percent of the patients who completed the study had a bodyweight increase of more than 5 kg. Body weight gain was more expressed during the first 3 months but continued until the end of the study. Thus, bodyweight gain was confirmed as a frequent adverse effect of pregabalin in the treatment of epilepsy. However, further explorative analyses revealed that the number of anticonvulsant drugs, representing total antiepileptic drug load, is an essential mediator of the bodyweight gain effect of pregabalin. If re-analyses of former data or future studies confirm this finding, the risk of bodyweight gain may be more limited to patients receiving polytherapy. Bodyweight gain was neither reflected by Adverse Event Profile total scores nor by the score of the bodyweight gain item of this questionnaire (#14) indicating that subjective evaluations are rather independent of the objective burden. A third of the patients (N = 37) prematurely exited the study due to side effects or the lack of therapeutic effect but only two of the patients discontinued pregabalin medication due to bodyweight gain.
The embedded randomized controlled trial showed that a short patient counseling program on bodyweight control was without any effect although a stronger increase of pregabalin dosages from the 3-to 6-month follow-up in the standard counseling condition biased the study towards positive effects of counseling. Thus, within the organizational framework of an outpatient clinic, the risk of bodyweight gain under pregabalin treatment could not be controlled efficiently. This does not preclude that more extensive interventional programs together with a more efficient control of patient compliance may be more successful.
The mechanisms underlying bodyweight gain due to anticonvulsant therapies are not fully clear yet and may differ between drugs.
1,2 Firstly, increased food uptake may occur in the consequence of peripheral mechanisms relying on drug-induced lowering of the blood glucose level (e.g., due to increased insulin or decreased carnitine levels) or more directly on central mechanisms underlying appetite regulation. Secondly, drugs may alter energy consumption (e.g., sedating effects by altered GABAergic inhibitory neurotransmission). Thirdly, bodyweight may increase due to an anti-diuretic effect of the drug and increased storage of water in the tissue (oedema). 9 The design of this present study does not allow a thorough analysis of the mechanisms underlying bodyweight gain under pregabalin treatment. For example, bodyweight measurement did not include a body fat and water percentage analysis. Therefore, it is unclear whether bodyweight gain resulted from metabolic changes, i.e. increased food uptake or decreased energy consumption, anti-diuretic effects or both. Freynhagen et al. reported that pregabalin as a new treatment for neuropathic pain produced bodyweight gain but did not affect diabetes control (blood glucose level). 9 Several patients of that study showed peripheral oedema indicating a possible contribution of an anti-diuretic effect. Of course, extended counseling aiming at the control of energy uptake and consumption would be ineffective regarding possible anti-diuretic effects of pregabalin. However, it appears unlikely that a median bodyweight gain of 4.0 kg during 6 months could be explained by an anti-diuretic mechanism only. Furthermore, this present study shows an important contribution of the total anticonvulsant drug load indicating cumulative effects of the entire medication on bodyweight alteration instead of a specific pregabalin effect.
Conclusions
Bodyweight gain may be a risk during pregabalin treatment in epilepsy particularly in patients with high anticonvulsant drug load. This risk cannot be controlled by extended counseling on bodyweight control under the usual organizational conditions of an outpatient clinic.
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Appendix A
Patient handout: Bodyweight Control under Lyrica TM (pregabalin) Treatment Dear Patient--studies have confirmed that Lyrica TM (pregabalin) is an efficient and well-tolerated anticonvulsant drug. However, one of the possible side effects is bodyweight gain. We want to give you some further information on how you may prevent this side effect.
Bodyweight gain is only possible if the energy taken up by eating and drinking (calories) is higher than the energy actually needed by the body. The body already consumes a lot of energy just to maintain the basic functions (e.g., body temperature) but also for the daily activities. Therefore, we ask you to observe the following rules: 
